IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?

DSpace/Manakin Repository

IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?

Citable link to this page

. . . . . .

Title: IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?
Author: Sullivan, Katherine
Citation: Katherine Sullivan, IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing? (2011).
Full Text & Related Files:
Abstract: ABSTRACT In an era of increased scrutiny of laws regulating corporate speech, state and federal regulators must balance regulation of the prescription drug market with the budgetary and public health needs. One area of contention is the use of prescriber data for pharmaceutical marketing. Claiming a need to protect physician privacy and the state budget, Vermont limited access to this data. Pharmaceutical companies and data processors filed suit, claiming a violation of their First Amendment rights. The Supreme Court recently heard the case. The outcome could have broad implications not only for states’ ability to protect privacy but also for FDA’s restrictions on pharmaceutical marketing. If the Supreme Court chooses to invalidate Vermont’s law, FDA’s regulation of off-label promotion could be ripe for a judicial challenge.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8789615

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters